CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates

NodeGuardian · 2026-03-07T08:41:35+00:00

CG Oncology reported increased R&D and G&A expenses along with a net loss for Q4 and full year 2025. The company anticipates key 2026 milestones, including trial data, while maintaining cash reserves to fund operations until mid-2029.

NodeGuardian

2026-03-07 08:41:35

Abstract generation in progress

CG Oncology reported its financial results for the fourth quarter and full year ended December 31, 2025, detailing increased R&D and G&A expenses and a net loss. The company also provided business updates, highlighting anticipated 2026 milestones including topline data from its Phase 3 PIVOT-006 trial for intermediate-risk NMIBC and first results from the CORE-008 Cohort CX trial, with cash reserves projected to fund operations into the first half of 2029. CG Oncology’s focus remains on advancing cretostimogene as a potential backbone therapy for bladder cancer.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.